NEW ANALYSES PRESENTED AT ASH 2015 DEMONSTRATE THE POTENTIAL OF KYPROLIS® (CARFILZOMIB) AS BACKBONE THERAPY IN MULTIPLE MYELOMA
Data Confirm Efficacy and Safety of Kyprolis Combination Across Range of Patient Populations
Data Confirm Efficacy and Safety of Kyprolis Combination Across Range of Patient Populations
CHMP rekommenderar EU-kommissionen att godkänna Kyprolis för behandling av myelom, en elakartad cancer i benmärgen. – Det här är en potent behandling som påtagligt förlänger tiden utan sjukdomsutveckling samtidigt som biverkningsprofilen är fullt acceptabel, säger Hareth Nahi, överläkare vid Karolinska Universitetssjukhuset och en av landets ledande experter på myelom.
Pivotal Study Showed Patients Treated With Kyprolis in Combination With Standard of Care Lived Nearly 50 Percent Longer Without Disease Worsening Compared to Standard of Care Alone
Amgen discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.se
Gustav III:s Boulevard 54
169 27 Solna
Sverige